Q3 EBITDA was 19% higher than our estimate led by strong growth in key markets Domestic formulations (up 13.5% YoY vs. our est. 8%) and US (up 30% YoY vs our est. 16%) leading to gross margin expansion of 300 bps (both YoY/QoQ).